Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy
Open Access
- 22 December 2016
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 1 (21) , e90733
Abstract
Angiogenesis and co-optive vascular remodeling are prerequisites of solid tumor growth. Vascular heterogeneity, notably perivascular composition, may play a critical role in determining the rate of cancer progression. The contribution of vascular pericyte heterogeneity to cancer progression and therapy response is unknown. Here, we show that angiopoietin-2 (Ang2) orchestrates pericyte heterogeneity in breast cancer with an effect on metastatic disease and response to chemotherapy. Using multispectral imaging of human breast tumor specimens, we report that perivascular composition, as defined by the ratio of PDGFRβ – and desmin + pericytes, provides information about the response to epirubicin but not paclitaxel. Using 17 distinct patient-derived breast cancer xenografts, we demonstrate a cancer cell–derived influence on stromal Ang2 production and a cancer cell–defined control over tumor vasculature and perivascular heterogeneity. The aggressive features of tumors and their distinct response to therapies may thus emerge by the cancer cell–defined engagement of distinct and heterogeneous angiogenic programs.Keywords
This publication has 58 references indexed in Scilit:
- Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivoMolecular Oncology, 2015
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling BlockadeCell Reports, 2014
- TP53status predicts long-term survival in locally advanced breast cancer after primary chemotherapyActa Oncologica, 2014
- Angiopoietin‐2 mediates blood–brain barrier impairment and colonization of triple‐negative breast cancer cells in brainThe Journal of Pathology, 2013
- Perfusion Heterogeneity in Breast Tumors for Assessment of AngiogenesisJournal of Ultrasound in Medicine, 2013
- Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor TherapyCancer Research, 2013
- Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trialsCancer Treatment Reviews, 2012
- Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung MetastasisJNCI: Journal of the National Cancer Institute, 2012
- CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast CancerPLOS ONE, 2008
- The Tie-2 ligand Angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanismJournal of Cell Science, 2005